Prestige Consumer Healthcare Inc.

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
68.35 ^USD	+0.47%		-1.21%	+11.65%

Feb. 16	Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing	MT
Feb. 16	Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing	MT

Prestige Consumer Healthcare Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022

August 04, 2022 at 06:00 am EDT

Prestige Consumer Healthcare Inc. reported earnings results for the first quarter ended June 30, 2022. For the first quarter, the company reported sales was USD 277.06 million compared to USD 269.18 million a year ago. Net income was USD 55.27 million compared to USD 57.76 million a year ago. Basic earnings per share from continuing operations was USD 1.1 compared to USD 1.15 a year ago. Diluted earnings per share from continuing operations was USD 1.09 compared to USD 1.14 a year ago.

Latest news about Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing	Feb. 16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing	Feb. 16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $368,184, According to a Recent SEC Filing	Feb. 12	MT
Prestige Consumer Healthcare's Fiscal Q3 Earnings, Revenue Increase; Raises 2024 Earnings Guidance; Shares Gain	Feb. 08	MT
Transcript : Prestige Consumer Healthcare Inc., Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08
North American Morning Briefing : S&P 500 to Open -2-	Feb. 08	DJ
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 Revenue $282.7M, vs. Street Est of $280.4M	Feb. 08	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 EPS $1.06, vs. Street Est of $1.04	Feb. 08	MT
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Prestige Consumer Healthcare Inc. Revises Earnings Guidance for the Year of Fiscal 2024	Feb. 08	CI
Prestige Consumer Healthcare Unit Recalls 2 Lots of Ting Antifungal Spray Liquid on High Levels of Benzene	Feb. 02	MT
Prestige Consumer Healthcare Unit Recalls One Lot of Anesthetic Spray Due to Benzene Presence	Dec. 22	MT
Prestige Consumer Healthcare Unit Recalls 2 Lots of Antifungal Spray Powder Due to High Levels of Benzene	Nov. 24	MT
Transcript : Prestige Consumer Healthcare Inc., Q2 2024 Earnings Call, Nov 02, 2023	Nov. 02
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q2 Revenue $286.3M, vs. Street Est of $285.2M	Nov. 02	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q2 EPS $1.07, vs. Street Est of $1.07	Nov. 02	MT
Prestige Consumer Healthcare Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024	Nov. 02	CI
Prestige Consumer Healthcare Insider Sold Shares Worth $149,657, According to a Recent SEC Filing	23-09-18	MT
Transcript : Prestige Consumer Healthcare Inc. Presents at Barclays Global Consumer Staples Conference 2023, Sep-07-2023 03:00 PM	23-09-07
Insider Sell: Prestige Consumer Healthcare	23-08-09	MT
Transcript : Prestige Consumer Healthcare Inc., Q1 2024 Earnings Call, Aug 03, 2023	23-08-03
Prestige Consumer Healthcare Fiscal Q1 Earnings Fall, Revenue Rises; Fiscal-Year 2024 Outlook Reaffirmed	23-08-03	MT
Tranche Update on Prestige Consumer Healthcare Inc.'s Equity Buyback Plan announced on May 4, 2023.	23-08-03	CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q1 Revenue $279.3M, vs. Street Est of $278.4M	23-08-03	MT

Chart Prestige Consumer Healthcare Inc.

Duration

Period

More charts

Company Profile

Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summerâs Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreauxâs Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Prestige Consumer Healthcare Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

68.35 USD

Average target price

74.33 USD

Spread / Average Target

+8.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PRESTIGE CONSUMER HEALTHCARE INC.	+11.65%	3.39B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.76%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.02%	211B
NOVARTIS AG	-0.52%	203B
ROCHE HOLDING AG	-10.31%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals